Skip to main content

Advertisement

Table 3 Clinical cure rate at the isolate level: selected baseline isolates at test-of-cure visit (ME population)*

From: A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections

Isolate Tigecycline Comparator
  n/N % n/N %
Staphylococcus aureus 54/71 76.1 49/61 80.3
 MRSA 25/36 69.4 21/29 72.4
 CA-MRSA 17/25 68.0 17/23 73.9
 MSSA 29/35 82.9 28/32 87.5
Streptococcus spp. 30/36 83.3 15/25 60.0
S. pyogenes 8/11 72.7 5/5 100
S. agalactiae 9/9 100 3/6 50.0
S. anginosus groupa 8/9 88.9 3/8 37.5
Enterobacter cloacae 5/8 62.5 1/1 100
Enterococcus spp. b 5/7 71.4 6/6 100
Escherichia coli 10/13 76.9 7/8 87.5
Klebsiella pneumoniae 5/5 100 5/6 83.2
Proteus spp. c 4/7 57.1 2/2 100
Pseudomonas aeruginosa 5/7 71.4 2/2 100
  1. *No statistically significant differences between groups. ME, microbiologically evaluable; MRSA, methicillin-resistant Staphylococcus aureus; CA-MRSA, community-acquired MRSA; MSSA, methicillin-susceptible Staphylococcus aureus. a Streptococcus anginosis, Streptococcus intermedius, Streptococcus constellatus; b Enterococcus faecalis, Enterococcus faecium; c Proteus mirabilis, Proteus penneri, Proteus vulgaris group.